Mar 31, 2015
(A) CONTINGENT LIABILITIES NOT PROVIDED FOR
F.Y.
2014-15 F.Y.
2013-14
(i) Claims against the company not
acknowledged as debts Nil Nil
(ii) Estimated amounts of contracts remaining to
be executed on Capital Accounts and not provided for Nil Nil
(B) IN THE OPINION OF DIRECTORS
(i) The current assets and loans and advances are approximately of
value stated if realized in the ordinary course of business except to
the extent of impairment, if any.
(ii) The provision for all known liabilities is adequate and considered
reasonable.
(C) Balances of Sundry Debtors, Creditors and other Advances are
subject to confirmation/reconciliation and consequential adjustment if
any arising there to shall be considered in due course of time.
(D) RETIREMENT BENEFITS
Liability for Gratuity and Leave encashment is being provided based
upon the certificate of Actuarial at the end of the year. _____
(E) Segment Reporting (AS-17)
1- Primary Segment: The identification of Business segment is done in
accordance with the system adopted for internal financial reporting to
the board of directors and management structure. The company has
identified products as primary segment.
2- Secondary Segment: The company had operated in one segment only.
Mar 31, 2014
(A) CONTINGENT LIABILITIES NOT PROVIDED FOR
F.Y. 2013-14 F.Y. 2012-13
(i) Claims against the company not Nil Nil
acknowledged as debts
(ii) Estimated amounts of contracts Nil Nil
(B) IN THE OPINION OF DIRECTORS
(i) The current assets and loans and advances are approximately of
value stated if realized in the ordinary course of business except to
the extent of impairment, if any.
(ii) The provision for ail known liabilities is adequate and considered
reasonable.
(C) Balances of Sundry Debtors, Creditors and other Advances are
subject to confirmation/reconciliation , and consequential adjustment
if any arising there to shall be considered in due course of time.
(D) RETIREMENT BENEFITS
Liability for Gratuity and Leave encashment is being provided based
upon the certificate of Acturian at the end of the year.
(H) Related Party Disclosure
(a) Related party disclosures as required to by AS-18 are given below:
Companies/Firms in which Directors & their relative are interested:-
Name of Concern Relationship
M/s Brawn Laboratories Ltd. Associate Company by virtue of
Common Directors
M/s OverseasLaboratories Pvt. Ltd. Associate Company by virtue, of
Common Directors
M/s Delhi Pharma Associate firm by virtue of
relative of Director is proprietor
M/s Fine Pharmachem Associate firm by virtue of
relative of Director is proprietor
M/s South Delhi Medicos Associate firm by virtue of
relative of Director is proprietor
M/s Sai Corporation Associate firm by virtue of
relative of Director is proprietor
Directors:
Mr. Brij Raj Gupta
Mrs. Brij Bala Gupta
Mrs. Urmila Gupta
Mr. Mahesh Kumar Nanchal
Mr. Manohar Lai
Mr. Trilok Singh
Relatives of Director:
Mr. A. K. Gupta
Mrs. Shashi Bala Gupta
Dr. Atul Gupta
Mr. Nitin Gupta
Mr. Love Gupta
Mr. Kush GuDta .
(I) Segment Reporting (AS-17)
1- Primary Segment: The identification of Business segment is done in
accordance with the system adopted for internal financial reporting to
the board of directors and management structure. The company has
identified products as primary segment.
2- Secondary Segment: The company had operated in one segment only.
(M) Expenses on extraordinary items amounting to Rs.7762.72 Thousand
(Rs. Nil) are related to the expiry of claim of the company on account
of DEPB amounting to Rs.4140.00 Thousand and a sum of Rs.3622.72
Thousand on account ofexpiry&breakage claims ofthe third parties.
(N) Previous year''s figures have been regrouped/rearranged wherever
necessary to make them comparable withcurrentyearfigures.
Voting rights of shareholders: As per article 76 of the Articles of
Association of the Company,
a. on show of hands, every member present in person shall have one
vote;
b. on a poll, the voting rights of the members shall be as laid down in
section 87 of the Companies Act, 1956.
Mar 31, 2012
(A) CONTINGENT LIABILITIES NOT PROVIDED FOR
(i) Claims against the company not acknowledged as debts: Nil
(ii) Estimated amounts of contracts remaining to be executed on Capital
Accounts and not provided for Nil (Previous Year Nil).
(B) IN THE OPINION OF DIRECTORS
(a) The current assets and loans and advances are approximately of
value stated if realized in the ordinary course of business except to
the extent of impairment, if any.
(b) The provision for all known liabilities is adequate and considered
reasonable.
(C) Balances of Sundry Debtors, Creditors and other Advances are
subject to confirmation/ reconciliation and consequential adjustment if
any arising there to shall be considered in due course of time.
(D) RETIREMENT BENEFITS
Liability for Gratuity and Leave encashment is being provided based
upon the certificate of Actuarial at the end of the year.
(E) Related Party Disclosure
(a) Related party disclosures as required to by AS-18 are given below:
Companies/Firms in which Directors & their relative are interested:-
Name of Concern
M/s Brawn Laboratories Ltd.
M/s Overseas Laboratories( P) Ltd.
M/s Delhi Pharma
M/s Fine Pharmachem
M/s South Delhi Medicos
Relationship
Associate Company by virtue of Common Directors
Associate Company by virtue of Common Directors
Associate firm by virtue of relative of Director is proprietor
Associate firm by virtue of relative of Director is proprietor
Associate firm by virtue of relative of Director is proprietor
Directors:
Mr. Brij Raj Gupta
Mrs.Brij Bala Gupta
Mrs. Urmila Gupta
Mr.Mahesh Kumar Nanchai
Mr. Manohar Lai
Mr. Bal Kishan Sharma
Relatives of Director:
Mr. A.K.Gupta
Mrs.Shashi Bala Gupta
Dr. Atul Gupta
Mr.NitinGupta
MrLoveGupta
Mr. Kush Gupta
(F) In view of the insufficient information from the suppliers
regarding their status as SSI units, the amount due to small scale
industrial undertaking can not be ascertained.
(G) The variation in profit shown in unaudited results/ published is
due to provisions for retirement benefits as on date of 31st March
2012.
(H) Previous year''s figures have been regrouped/rearranged wherever
necessary to make them comparable with current year figures.
Mar 31, 2011
(A) CONTINGENT LIABILITIES NOT PROVIDED FOR
(i) Claims against the company not acknowledged as debts: Nil
(ii) Estimated amounts of contracts remaining to be executed on Capital
Accounts and not provided for Nil (Previous Year Nil)
(B) IN THE OPINION OF DIRECTORS
(a) The current assets and loans and advances are approximately of
value stated if realized in the ordinary course of business except to
the extent of impairment, if any.
(b) The provision for all known liabilities is adequate and considered
reasonable.
(C) Balances of Sundry Debtors, Creditors and other Advances are
subject to confirmation/reconciliation and consequential adjustment if
any arising there to shall be considered in due course of time.
(D) RETIREMENT BENEFITS
Liability for Gratuity and leave encashment is being provided based
upon the certificate of Acturian at the end of the year.
(E) Refer Schedule -7, The Company has recognized recoverable claim of
Rs.41.40 Lac (Rs.41.40 Lac), arised on account of custom duty credit on
export sales. These claims are recoverable subject to receipt of export
payments, which are overdue and under litigation. The management
considered these debtors as good and hence no provision is considered
necessary.
(I) Related Party Disclosure
(a) Related party disclosures as required to by AS -18 are given below:
Companies/Firms in which Directors & their relative are interested:
Name of Concern Relationship
M/S Brawn Laboratories Ltd. Associate Company by virtue of
Common Directors
M/S Overseas Laboratories
(P) Ltd. Associate Company by virtue of
Common Directors
M/S Delhi Pharma Associate firm by virtue of
relative of Director is proprietor
M/S Fine Pharmachem Associate firm by virtue of relative
of Director is proprietor
Directors:
Mr. Brij Raj Gupta
Mrs. Brij Bala Gupta
Mrs. Urmila Gupta
Mr. Mahesh Kumar Nanchal
Mr. Manohar Lal
Mr. Bal Kishan Sharma
Relatives of Director:
Mr. A.K.Gupta
Mrs.Shashi Bala Gupta
Dr. Atul Gupta
Mr. Nitin Gupta
Mr. Love Gupta
Mr. Kush Gupta
(J) Segment Reporting (AS-17)
1. Primary Segment: The identification of Business segment is done in
accordance with the system adopted for internal financial reporting to
the board of directors and management structure. The company has
identified products as primary segment.
(L) There is no amount remaining unpaid to Small Scale Suppliers within
the meaning of "The interest on Delayed Payments to Small Scale and
Ancillary Undertaking Act".
(M) Additional information pursuant to provisions of paragraph 3 & 4 of
part (ii) schedule (vi) to the Companies Act, 1956 (As certified by the
management and accepted by the auditors).
(a) The Company had no manufacturing activities during the year. The
company got its products manufactured from other parties and hence the
information regarding installed capacity is not given.
(N) The variation in profit shown in unaudited results/ published is
due to reversal of VAT recoveries and provisions for retiremental
benefits as on date of 31st March 2011.
(P) Previous year's figures have been regrouped/rearranged whenever
necessary to make them comparable with current year figures.
Mar 31, 2010
(A) CONTINGENT LIABILITIES NOT PROVIDED FOR
(i) Claims against the company not acknowledged as debts: Nil
(ii) Estimated amounts of contracts remaining to be executed on Capital
Accounts and not provided for Nil(Previous Year Nil)
(B) IN THE OPINION OF DIRECTORS
(a) The current assets and loans and advances are approximately of
value stated if realized in the ordinary course of business except to
the extent of impairment, if any.
(b) The provision for all known liabilities is adequate and considered
reasonable.
(C) Balances of Sundry Debtors, Creditors and other Advances are
subject to confirmation/reconciliation and consequential adjustment if
any arising there to shall be considered in due course of time.
(D) RETIREMENT BENEFITS
Liability for Gratuity is being provided based upon the certificate of
Acturian at the end of the year.
(E) Refer Schedule -7, The Company has recognized recoverable claim of
Rs.41.40 Lac (Rs.41.40 Lac), arised on account of custom duty credit on
export sales. These claims are recoverable subject to receipt of export
payments, which are overdue and under litigation. The management
considered these debtors as good and hence no provision is considered
necessary.
(F) Related Party Disclosure
(a) Related party disclosures as required to by AS-18 are given below:
Companies/Firms in which Directors & their relative are interested:-
M/S Brawn Laboratories Ltd.
M/S A.B.Pharma (P) Ltd.
M/S Overseas Laboratories (P) Ltd.
M/S Delhi Pharma
M/S Fine Pharmachem
Directors:
Mr. Brij Raj Gupta
Mrs. Brij Bala Gupta
Mrs. Urmila Gupta
Mr. Mahesh Kumar Nanchal
Mr. Manohar Lal
Mr. Bal Kishan Sharma
Relatives of Director :
Mr. A.K.Gupta
Mrs. Shashi Bala Gupta
Dr. Atul Gupta
Mr. Nitin Gupta
Mr. Love Gupta
Mr. Kush Gupta
Transactions with related party:
S.No. Name of Company/Firm Nature of transaction Amount
1. M/s Brawn Laboratories Ltd. Purchases Rs.81.63 Lac
2. M/s Brawn Laboratories Ltd. Commission Received Rs.3.94 Lac
3. M/s Brawn Laboratories Ltd. Discount Income Rs.18.85 Lac
4. M/s Brawn Laboratories Ltd. Consultancy Fee Rs.7.50 Lac
5. M/s Delhi Pharma Sales Rs.0.90 Lac
(G) There is no amount remaining unpaid to Small Scale Suppliers within
the meaning of "The interest on Delayed Payments to Small Scale and
Ancillary Undertaking Act".
(H) Additional information pursuant to provisions of paragraph 3 & 4 of
part (ii) schedule (vi) to the Companies Act, 1956 (As certified by the
management and accepted by the auditors).
(a) The Company had no manufacturing activities during the year. The
company got its products manufactured from other parties on loan
licenses basis and hence the information regarding installed capacity
is not given.
(I) Previous years figures have been regrouped/rearranged wherever
necessary to make them comparable with current year figures.